Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 158,313Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 2Daliresp

02 8Daliresp/Daxas

PharmaCompass

01

Brand Name : Daliresp/Daxas

Roflumilast

arrow
Antibody Engineering
Not Confirmed

Brand Name : Daliresp/Daxas

arrow
Antibody Engineering
Not Confirmed

Roflumilast

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 217

2019 Revenue in Millions : 215

Growth (%) : 1

blank

02

Brand Name : Daliresp/Daxas

Roflumilast

arrow
Antibody Engineering
Not Confirmed

Brand Name : Daliresp/Daxas

arrow
Antibody Engineering
Not Confirmed

Roflumilast

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 227

2020 Revenue in Millions : 217

Growth (%) : 5

blank

03

Brand Name : Daliresp/Daxas

Roflumilast

arrow
Antibody Engineering
Not Confirmed

Brand Name : Daliresp/Daxas

arrow
Antibody Engineering
Not Confirmed

Roflumilast

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 189

2021 Revenue in Millions : 227

Growth (%) : -17

blank

04

Brand Name : Daliresp/Daxas

Roflumilast

arrow
Antibody Engineering
Not Confirmed

Brand Name : Daliresp/Daxas

arrow
Antibody Engineering
Not Confirmed

Roflumilast

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2023 Revenue in Millions : 54

2022 Revenue in Millions : 189

Growth (%) : -71

blank

05

Brand Name : Daliresp

Roflumilast

arrow
Antibody Engineering
Not Confirmed

Brand Name : Daliresp

arrow
Antibody Engineering
Not Confirmed

Roflumilast

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2015 Revenue in Millions : 0

2014 Revenue in Millions : 104

Growth (%) : New Launch

blank

06

Brand Name : Daliresp/Daxas

Roflumilast

arrow
Antibody Engineering
Not Confirmed

Brand Name : Daliresp/Daxas

arrow
Antibody Engineering
Not Confirmed

Roflumilast

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2017 Revenue in Millions : 198

2016 Revenue in Millions : 154

Growth (%) : 29

blank

07

Brand Name : Daliresp/Daxas

Roflumilast

arrow
Antibody Engineering
Not Confirmed

Brand Name : Daliresp/Daxas

arrow
Antibody Engineering
Not Confirmed

Roflumilast

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2018 Revenue in Millions : 189

2017 Revenue in Millions : 198

Growth (%) : -5%

blank

08

Brand Name : Daliresp/Daxas

Roflumilast

arrow
Antibody Engineering
Not Confirmed

Brand Name : Daliresp/Daxas

arrow
Antibody Engineering
Not Confirmed

Roflumilast

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2016 Revenue in Millions : 154

2015 Revenue in Millions : 104

Growth (%) : 48

blank

09

Brand Name : Daliresp/Daxas

Roflumilast

arrow
Antibody Engineering
Not Confirmed

Brand Name : Daliresp/Daxas

arrow
Antibody Engineering
Not Confirmed

Roflumilast

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2019 Revenue in Millions : 215

2018 Revenue in Millions : 189

Growth (%) : 14

blank

10

Brand Name : Daliresp

Roflumilast

arrow
Antibody Engineering
Not Confirmed

Brand Name : Daliresp

arrow
Antibody Engineering
Not Confirmed

Roflumilast

Main Therapeutic Indication : Respiratory disorders

Currency : USD

2014 Revenue in Millions :

2013 Revenue in Millions :

Growth (%) :

blank